Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Fiduciary Trust Co

Fiduciary Trust Co grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,522 shares of the biopharmaceutical company’s stock after buying an additional 26 shares during the quarter. Fiduciary Trust Co’s holdings in Regeneron Pharmaceuticals were worth $8,959,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. SteelPeak Wealth LLC raised its position in Regeneron Pharmaceuticals by 173.0% during the second quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock worth $1,148,000 after acquiring an additional 692 shares during the last quarter. Atria Investments Inc raised its position in shares of Regeneron Pharmaceuticals by 12.2% during the 1st quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock worth $8,317,000 after purchasing an additional 941 shares during the last quarter. Mizuho Securities USA LLC lifted its stake in Regeneron Pharmaceuticals by 625.5% in the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after buying an additional 51,162 shares in the last quarter. Tri Locum Partners LP grew its holdings in Regeneron Pharmaceuticals by 104.5% during the 2nd quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock valued at $18,410,000 after buying an additional 8,949 shares during the last quarter. Finally, Tidal Investments LLC increased its position in Regeneron Pharmaceuticals by 16.8% during the first quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock worth $4,774,000 after buying an additional 711 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $754.87 on Thursday. The business’s 50-day simple moving average is $921.45 and its 200 day simple moving average is $1,022.55. The company has a market cap of $82.95 billion, a P/E ratio of 18.68, a PEG ratio of 2.89 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a one year low of $735.95 and a one year high of $1,211.20.

Analyst Ratings Changes

A number of analysts recently commented on REGN shares. Leerink Partnrs lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Morgan Stanley lowered their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a report on Friday, November 1st. BMO Capital Markets reduced their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Truist Financial cut their price target on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a report on Friday, November 1st. Finally, Royal Bank of Canada decreased their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $1,099.55.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.